IP Library › Patent Application 13923071
Patent Application
App. No. 13/923,071

PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/923,071
Abstract

The method of treating patients by administering N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea for treatment of leukotriene related pathologies, and compositions for this use.

Claims (26)

1 . A composition comprising R- and S-enantiomers of N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea or pharmaceutically effective salts thereof wherein the composition comprises less than 1% of the S-enantiomer.

2 . (canceled)

3 . The composition of claim 1 , wherein the composition consists of R- and S-enantiomers of N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea or pharmaceutically effective salts thereof.

4 . The composition of claim 3 , wherein the composition consists of less than 1% of the S-enantiomer.

5 . The composition of claim 1 , wherein the composition is provided in a unit dosage form for oral administration and wherein the composition is present in an amount of about 25-100 mg.

6 . The composition of claim 5 , wherein the composition is present in an amount of about 25, 50, 75, or 100 mg.

7 . The composition of claim 5 , wherein the composition is present in an amount of about 100 mg.

8 . The composition of claim 5 , wherein said unit oral dosage form is a tablet or capsule.

9 . A method for preventing or treating a leukotriene related pathology in a subject in need thereof, comprising administering to the subject the composition of claim 1 .

10 . The method of claim 9 , wherein the subject is a human.

11 - 14 . (canceled)

15 . The method of claim 9 , wherein the pathology is atherosclerotic plaque.

16 . The method of claim 15 , wherein the method is effective in preventing or treating an acute cardiovascular event resulting from atherosclerotic plaque.

17 . The method of claim 16 , wherein the acute cardiovascular event is heart attack.

18 . The method of claim 16 , wherein the acute cardiovascular event is stroke.

19 . The method of claim 15 , wherein the subject has previously had acute coronary syndrome.

20 . The method of claim 9 , wherein the pathology is a cardiovascular disease.

21 . The method of claim 20 , wherein the cardiovascular disease is caused by atherosclerotic plaque.

22 . The method of claim 20 , wherein the cardiovascular disease results in heart attack.

23 . The method of claim 20 , wherein the cardiovascular disease results in stroke.

24 . The method of claim 20 , wherein the cardiovascular disease results in ischemia induced myocardial injury.

25 . The method of claim 20 , wherein the cardiovascular disease is peripheral arterial disease.

26 . The method of claim 20 , wherein the cardiovascular disease is acute coronary syndrome.

27 . The method of claim 20 , wherein the subject has previously had acute coronary syndrome.

28 . A pharmaceutical formulation comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

29 . The pharmaceutical formulation of claim 28 , wherein the composition consists of R- and S-enantiomers of N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea or pharmaceutically effective salts thereof.